23.06.2026

Press Release

New European Project PHOENIX launches to develop safer treatments for children with high-risk cancer + info

30.05.2026

Press Release

ABILITYPHARMA PRESENTS RESULTS AT ASCO 2026 OF THE PHASE IIB PANC-ASAP STUDY WITH IBRILATAZAR (ABTL0812) + info

05.06.2025

Press Release

ABILITYPHARMA'S IBRILATAZAR (ABTL0812) DOUBLES OVERALL SURVIVAL IN PATIENTS WITH SQUAMOUS NON-SMALL CELL LUNG CANCER + info

09.09.2024

Press Release

IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info

30.07.2024

Press Release

AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info

16.07.2024

Press Release

AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info

11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info

02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info

14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info